Altogether, our results suggest that HDAC6 controls SIRPα expression in macrophages and melanoma patients and that HDAC6i can be used to downregulate the expression of anti-phagocytic signals and upregulate pro-phagocytic signals, which may enhance the phagocytic capacity of macrophages. Here, SIRPA is linked to melanoma.